ulf Jungnelius

Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe

GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a patent covering the clinical use of a biomarker analysis to detect cancer patients ability to respond to folate-based therapy cancer treatments and an intention-to-grant patent application for a patent covering the AGENT study dose regimen in Europe.

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and marketing with a particular focus on oncology.

New Chairman and extended board at Isofol Medical AB (publ)

Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday 10 October. The present Chairman, Jan-Eric Österlund, is resigning and the Nomination Committee is proposing Dr Ulf Jungnelius as new Chairman. The Committee is also proposing an increased board with three new directors.

Scroll to Top